CVS Health Corporation $CVS Shares Purchased by Rhumbline Advisers

Rhumbline Advisers raised its holdings in shares of CVS Health Corporation (NYSE:CVS) by 0.4% in the third quarter, Holdings Channel.com reports. The firm owned 2,398,761 shares of the pharmacy operator’s stock after buying an additional 8,598 shares during the period. Rhumbline Advisers’ holdings in CVS Health were worth $180,842,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Norges Bank bought a new stake in shares of CVS Health in the 2nd quarter worth about $1,358,698,000. Invesco Ltd. raised its stake in CVS Health by 15.3% during the second quarter. Invesco Ltd. now owns 23,532,479 shares of the pharmacy operator’s stock valued at $1,623,270,000 after buying an additional 3,118,626 shares in the last quarter. Jennison Associates LLC grew its position in shares of CVS Health by 111.7% in the 2nd quarter. Jennison Associates LLC now owns 4,014,139 shares of the pharmacy operator’s stock worth $276,895,000 after acquiring an additional 2,117,798 shares in the last quarter. Vanguard Group Inc. raised its position in shares of CVS Health by 1.7% during the 2nd quarter. Vanguard Group Inc. now owns 120,399,131 shares of the pharmacy operator’s stock valued at $8,305,132,000 after acquiring an additional 2,063,737 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in CVS Health by 153.0% in the second quarter. Arrowstreet Capital Limited Partnership now owns 3,105,827 shares of the pharmacy operator’s stock worth $214,240,000 after purchasing an additional 1,878,217 shares during the period. 80.66% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CVS has been the topic of a number of research reports. Mizuho increased their price target on CVS Health from $88.00 to $95.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 10th. Piper Sandler reiterated an “overweight” rating and issued a $101.00 target price (up from $99.00) on shares of CVS Health in a research note on Wednesday, December 10th. Leerink Partners upped their price target on shares of CVS Health from $86.00 to $95.00 and gave the stock an “outperform” rating in a research report on Thursday, October 16th. UBS Group reiterated an “outperform” rating on shares of CVS Health in a research report on Wednesday, December 10th. Finally, JPMorgan Chase & Co. upped their target price on shares of CVS Health from $93.00 to $101.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. Nineteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, CVS Health has an average rating of “Moderate Buy” and an average target price of $94.82.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Q4 revenue and adjusted EPS beat expectations — total revenue rose ~8.2% to $105.7B and adjusted EPS came in at $1.09, supporting the view that CVS’s turnaround is gaining traction. Read More.
• Positive Sentiment: Operational improvements: CVS completed a shift to cost‑based pharmacy reimbursement and reports improved prior‑authorization performance at Aetna — items that should help margins and predictability over time. Read More.
• Neutral Sentiment: Analyst tone is mixed but not uniformly negative — firms like Argus note pressure from Medicare proposals while retaining a favorable view of CVS’s long‑term positioning. Read More.
• Negative Sentiment: Medicare rate concerns: management called the 2027 Medicare Advantage rate notice “disappointing,” and ongoing Medicare proposal risks could compress MA margins and investor sentiment. This was a key reason shares weakened despite the beat. Read More.
• Negative Sentiment: Profit/guidance headwinds: while revenue was a record, some metrics disappointed — reports flagged lower full‑year profit vs. certain Street expectations, a lowered cash‑flow outlook in some commentary, and management provided an EPS range that some investors viewed as conservative, contributing to pre‑market weakness. Read More.

CVS Health Trading Down 0.3%

Shares of NYSE:CVS opened at $75.54 on Wednesday. CVS Health Corporation has a 12-month low of $54.06 and a 12-month high of $85.15. The company has a quick ratio of 0.63, a current ratio of 0.83 and a debt-to-equity ratio of 0.83. The firm has a market capitalization of $95.89 billion, a P/E ratio of 198.79, a price-to-earnings-growth ratio of 0.70 and a beta of 0.50. The firm has a fifty day moving average of $78.52 and a two-hundred day moving average of $75.98.

CVS Health (NYSE:CVS) last issued its earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.09. The company had revenue of $105.69 billion for the quarter, compared to analyst estimates of $103.67 billion. CVS Health had a return on equity of 11.45% and a net margin of 0.12%.The business’s revenue was up 8.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.19 EPS. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. On average, equities analysts expect that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Thursday, January 22nd were given a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, January 22nd. This represents a $2.66 dividend on an annualized basis and a yield of 3.5%. CVS Health’s payout ratio is currently 700.00%.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.